<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00075777</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-038</org_study_id>
    <secondary_id>U01CA070019</secondary_id>
    <secondary_id>CDR0000349348</secondary_id>
    <nct_id>NCT00075777</nct_id>
  </id_info>
  <brief_title>Valproic Acid in Treating Patients With Kaposi's Sarcoma</brief_title>
  <official_title>A Pilot Trial Of Valproic Acid In Patients With Kaposi's Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIDS Malignancy Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Emmes Company, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AIDS Malignancy Consortium</source>
  <brief_summary>
    <textblock>
      RATIONALE: Valproic acid may help stop the growth of Kaposi's sarcoma cells by blocking the&#xD;
      enzymes necessary for tumor cell growth.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying valproic acid in treating patients with HIV-related&#xD;
      Kaposi's sarcoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety of valproic acid in patients with Kaposi's sarcoma.&#xD;
&#xD;
        -  Determine the effects of this drug on human herpes virus 8 (KSHV) gene expression using&#xD;
           polymerase chain reaction and immunohistochemistry in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the effects of this drug on HIV, KSHV, and Epstein-Barr virus viral loads in&#xD;
           the plasma and peripheral blood mononuclear cells of these patients.&#xD;
&#xD;
        -  Determine clinical response in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is an open-label, pilot, multicenter study.&#xD;
&#xD;
      Patients receive oral valproic acid twice daily on days 1-28 followed by a drug taper over 2&#xD;
      weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed monthly for 6 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity-related discontinuation rate</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lytic induction rate</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical response rate</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Accelerated KS progression rate</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <enrollment type="Actual">19</enrollment>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valproic acid</intervention_name>
    <description>250 mg by mouth twice a day</description>
    <other_name>Depakene</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed HIV-related Kaposi's sarcoma (KS)&#xD;
&#xD;
               -  Disease involving the skin and/or lymph nodes&#xD;
&#xD;
                    -  No symptomatic visceral disease&#xD;
&#xD;
                    -  No oral KS as the only site of disease&#xD;
&#xD;
               -  Slowly progressive or stable disease allowed&#xD;
&#xD;
                    -  Slow progression defined as fewer than 5 new lesions per month&#xD;
&#xD;
               -  Must have documented HIV infection by positive ELISA, western Blot, or viral load&#xD;
                  determination&#xD;
&#xD;
          -  CD4 T-cell count &gt; 50/mm^3&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 750/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)*&#xD;
&#xD;
          -  AST and ALT ≤ 3 times ULN&#xD;
&#xD;
          -  Albumin &gt; 2.5 g/dL NOTE: *Elevated total bilirubin (≤ 3.5 mg/dL) secondary to&#xD;
             indinavir therapy allowed provided the direct bilirubin is normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No prior myocardial infarction&#xD;
&#xD;
          -  No evidence of cardiac ischemia&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             participation&#xD;
&#xD;
          -  No prior lactic acidosis &gt; 2.0 mmoles/L&#xD;
&#xD;
          -  No prior lipoatrophy or hypercholesterolemia secondary to retroviral treatment&#xD;
&#xD;
          -  No concurrent, acute, active opportunistic infection other than oral thrush or genital&#xD;
             herpes within the past 14 days&#xD;
&#xD;
          -  No other concurrent neoplasm requiring cytotoxic therapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 2 weeks since prior biologic therapy for KS&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 2 weeks since prior chemotherapy for KS&#xD;
&#xD;
          -  No concurrent systemic cytotoxic chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 2 weeks since prior radiotherapy for KS&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 2 weeks since other prior antineoplastic or local therapy for KS&#xD;
&#xD;
          -  More than 2 weeks since prior investigational therapy for KS&#xD;
&#xD;
          -  More than 60 days since prior local therapy to a KS-marker lesion unless lesion has&#xD;
             clearly progressed since therapy&#xD;
&#xD;
          -  More than 1 year since prior valproic acid&#xD;
&#xD;
          -  Concurrent antiretroviral therapy allowed provided regimen has been stable for at&#xD;
             least 4 weeks&#xD;
&#xD;
          -  No concurrent zidovudine&#xD;
&#xD;
          -  No other concurrent KS-specific therapy&#xD;
&#xD;
          -  No other concurrent investigational drugs, other than IND-approved antiretroviral&#xD;
             agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard F. Ambinder, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary Jo Lechowicz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Georgia Cancer Center for Excellence at Grady Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Center for Excellence at Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Barnes-Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Cancer Center at Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joan Karnell Cancer Center at Pennsylvania Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Floyd &amp; Delores Jones Cancer Institute at Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>January 9, 2004</study_first_submitted>
  <study_first_submitted_qc>January 12, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2004</study_first_posted>
  <last_update_submitted>August 27, 2014</last_update_submitted>
  <last_update_submitted_qc>August 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent Kaposi sarcoma</keyword>
  <keyword>AIDS-related Kaposi sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma, Kaposi</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

